2024-09-24 |
Week 4, September 2024: Anti-TIGIT Therapies |
2024-09-20 |
What is High-Throughput Expression and Production? |
2024-09-19 |
What are Antibody Therapeutics? |
2024-09-17 |
Week 3, September 2024: Preventive Measures |
2024-09-11 |
What are Bispecific Antibodies? |
2024-09-11 |
How High-Affinity Antibodies Improve Therapeutic Outcomes |
2024-09-10 |
Week 2, September 2024: Non-Small Cell Lung Cancer |
2024-09-03 |
Week 1, September 2024: Prurigo Nodularis & FDA Approvals |
2024-08-27 |
Week 4, August 2024: Anti-Drug Antibodies |
2024-08-26 |
Understanding the Difference Between ADC Biosimilars and ADC Isotypes |
2024-08-07 |
BIO Asia 2024 – Taiwan: Highlights and Event Recap |
2024-08-01 |
July 2024: Paroxysmal nocturnal hemoglobinuria (PNH) |
2024-07-24 |
Antibody-Drug Conjugates: A Brief |
2024-07-23 |
Week 4, July 2024: Healthspan and Lifespan |
2024-07-19 |
Therapeutic Antibodies in Medicine: An Overview |
2024-07-16 |
Week 3, July 2024: Immunostimulatory ADCs (iADCs) |
2024-07-09 |
Week 2, July 2024: An Update on Alzheimer’s Antibody Drugs |
2024-07-03 |
Week 1, July 2024: Blood Disorders |
2024-06-28 |
Immune Checkpoint Inhibitors and Antibody Therapeutics: A Paradigm Shift in Cancer Treatment |
2024-06-26 |
June 2024: SARS-CoV-2: What Now? |
2024-06-25 |
Week 4, June 2024: Immune Checkpoint Blockade |
2024-06-24 |
Next-Gen Immuno-Oncology Conference 2024 – Boston: Highlights and Event Recap |
2024-06-21 |
Antibody Basics: Part 10 - Therapeutic targets - Infectious Diseases |
2024-06-19 |
Afucosylated Antibodies: Mechanism of Action and Therapeutic Applications |
2024-06-18 |
Week 3, June 2024: Intravenous Immunoglobulin Therapy |
2024-06-17 |
Types of Payloads for Antibody-Drug Conjugates (ADCs) |
2024-06-14 |
Multi-Payload Antibody–Drug Conjugates |
2024-06-11 |
Week 2, June 2024: Ophthalmology in Focus |
2024-06-04 |
Week 1, June 2024: Multi-Payload ADCs |
2024-05-31 |
Antibody-Antibiotic Conjugates (AACs) in the Fight Against Bacterial Infections |